Katkin Keith
SEC CIK 1314596 · EDGAR
BoughtSold
Most active insiders at EBS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DeGolyer Donald W | Dir | — | $317.6K |
| 2 | Glessner Coleen | EVP, Quality, Ethics, CPL | — | $306.1K |
| 3 | Richard Ronald | Dir | — | $263.1K |
| 4 | Dayal Sujata Tyagi | Dir | — | $201.1K |
| 5 | Zoon Kathryn C | Dir | — | $144.5K |
| 6 | Katkin Keith | Dir | — | $128.2K |
| 7 | Williams Paul Anthony | SVP, Products Business | — | $59.0K |
| 8 | Lowry Simon C | SVP, CMO, R, D | — | — |
| 9 | Perl Jessica | SVP, GC, Corp Sec | — | — |
| 10 | Hartzel William | SVP, Bioservices | — | — |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-04 17:29 | 2026-04-30 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Dir | A - Grant | $0.00 | +25.3K | 111.8K | +29% | $0 |
| DT | 2026-05-04 17:29 | 2026-04-30 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Dir | S - Sale | $8.28 | -15.5K | 96.3K | -14% | -$128.2K |
| 2026-02-06 | 2026-02-04 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | A - Grant | $0.00 | +24.0K | 124.0K | +24% | $0 | |
| D | 2026-01-16 | 2026-01-10 | ELDN | Eledon Pharmaceuticals, Inc. | Katkin Keith | Dir | M - OptEx | $0.00 | +8,575 | 8,575 | New | $0 |
| 2025-05-28 | 2025-05-23 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Dir | S - Sale | $6.30 | -7,844 | 86.4K | -8% | -$49.4K | |
| 2025-05-19 | 2025-05-19 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | P - Purchase | $9.11 | +10.0K | 100.0K | +11% | +$91.1K | |
| D | 2025-05-02 | 2025-04-30 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Dir | A - Grant | $0.00 | +34.4K | 94.3K | +57% | $0 |
| 2025-02-07 | 2025-02-05 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | A - Grant | $0.00 | +25.0K | 90.0K | +38% | $0 | |
| D | 2024-05-28 | 2024-05-23 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Dir | A - Grant | $0.00 | +17.4K | 59.9K | +41% | $0 |
| 2024-02-09 | 2024-02-07 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | A - Grant | $0.00 | +17.0K | 65.0K | +35% | $0 | |
| 2023-05-30 | 2023-05-25 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Dir | A - Grant | $0.00 | +33.8K | 42.4K | +394% | $0 | |
| 2023-02-03 | 2023-02-02 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | A - Grant | $0.00 | +16.0K | 48.0K | +50% | $0 | |
| DM | 2022-10-07 | 2022-10-06 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | M - OptEx | $8.20 | +29.9K | 52.8K | +131% | +$245.2K |
| DM | 2022-10-07 | 2022-10-06 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | S - Sale+OE | $25.90 | -29.9K | 32.0K | -48% | -$774.4K |
| DM | 2022-10-04 | 2022-09-30+ | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | S - Sale+OE | $25.06 | -4,101 | 32.0K | -11% | -$102.8K |
| DM | 2022-10-04 | 2022-09-30+ | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | M - OptEx | $8.11 | +4,101 | 32.6K | +14% | +$33.2K |
| 2022-04-05 | 2022-04-02 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Dir | A - Grant | $0.00 | +8,595 | 8,595 | New | $0 | |
| 2022-02-03 | 2022-02-02 | SNDX | Syndax Pharmaceuticals Inc | Katkin Keith | Dir | A - Grant | $0.00 | +16.0K | 32.0K | +100% | $0 |
Purchase Sale Sale after option exercise All abbreviations